<DOC>
	<DOCNO>NCT02996500</DOCNO>
	<brief_summary>This Phase 2 , multicenter , randomize , double blind , double dummy , placebo active-controlled , parallel group study assess efficacy safety PF 06650833 Week 12 subject moderate-severe , active , RA inadequate response MTX . PF-06650833 match placebo tablet administer orally QD fast condition , tofacitinib match tofacitinib placebo tablet administer orally BID 12 week blind fashion .</brief_summary>
	<brief_title>Safety Efficacy Pf-06650833 In Subjects With Rheumatoid Arthritis , With An Inadequate Response To Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>1 . Male female ( include WOCBP ) subject age 18 70 year , inclusive . 2 . Diagnosis RA meeting 2010 American College Rheumatology ( ACR ) /European League Against Rheumatism ( EULAR ) classification criterion ( see Appendix 2 ) RA Total Score â‰¥6/10 . 3 . The subject active disease Screening Baseline , define : 6 joint tender painful motion , AND 6 joint swell ; fulfills 1 follow 2 criterion Screening : High sensitivity C reactive protein ( hsCRP ) &gt; 7 mg/L screen Erythrocyte sedimentation rate ( ESR ) ( Westergren method ) &gt; 28 mm/hr ; 4 . Meets Class I , II III ACR 1991 Revised Criteria Global Functional Status RA . 5 . Subjects must ACPA positive screen randomization . 6 . Subjects must take oral MTX least 3 month adequate dose determine subject inadequate response MTX 7 . Up 50 % subject may receive one ( one ) approve TNFinhibiting biologic agent administer inadequately effective and/or tolerate . The antiTNF biologic could also discontinue due lack continue access . 1 . Subjects know immunodeficiency disorder first degree relative hereditary immunodeficiency . 2 . Subjects follow infection infection history : 1 . Any infection require treatment within 2 week prior screen ( Visit 1 ) . 2 . Any infection require hospitalization , parenteral antimicrobial therapy within 60 day , otherwise judge opportunistic infection clinically significant investigator , within past 6 month . 3 . Infected joint prosthesis time prosthesis still situ . 4 . Recurrent ( one episode ) herpes zoster disseminate ( single episode ) herpes zoster disseminate ( single episode ) herpes simplex . 5 . Subjects screen HIV . Subjects test positive HIV exclude study . 6 . Subjects screen hepatitis B virus infection exclude positive hepatitis B surface antigen ( HBsAg ) . Subjects HBsAg negative test test positive hepatitis B core antibody ( HBcAb ) must test hepatitis B surface antibody ( HBsAb ) . If HBsAb negative , subject exclude study . 7 . Subjects clinically significant active hepatic disease hepatic impairment laboratory assessment . 8 . Subjects screen hepatitis C virus ( HCV Ab ) . Subjects positive HCV Ab test reflex test HCV ribonucleic acid ( HCV RNA ) . Only subject negative HCV Ab HCV RNA allow enroll study . 3 . Evidence active latent , untreated inadequately treated infection Mycobacterium tuberculosis ( TB ) 4 . Preexisting chronic autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>